HER2/neu expression plays an important role in the prognosis and treatment of breast cancer. HER2/neu overexpression occurred in both HER2-enriched and luminal HER2 subtypes. Purpose: Review some histopathological and immunohistochemical features of HER2/neu-positive breast carcinoma. Methods: 133 breast cancer patients were identified with overexpression of HER2/neu and determining the association with tumor grade, TNM stage, rick category, Ki67 index, Bcl2 status. Results: Grade III, HER2 subtypes (63,5%) had a higher rate than LUMBH+ (54,2%); Stage III, HER2 subtypes (25%) had a higher rate than LUMBH+ (21,3%); high risk, HER2 subtypes (49,4%) had a higher rate than LUMBH+ (45,8%); high Ki67, HER2 subtypes (48,2%) had a higher rate than LUMBH+ (45,8%); Bcl2 status, HER2 subtypes (21,2%) had a lower rate than LUMBH+ (68,8%). Conclusion: In HER2/neu-positive breast, HER2 subtypes has worse prognosis of some histopathological and immunohistochemical factors than LUMBH+.